HOMITB

Host and microbial molecular dissection of pathogenesis and immunity in tuberculosis

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: åsa
Cognome: Edström
Email: send email
Telefono: +46-8-524 871 40
Fax: +46-8-33 07 44

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 3˙931˙510 €
 EC contributo 2˙998˙251 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-11-01   -   2012-04-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: åsa
Cognome: Edström
Email: send email
Telefono: +46-8-524 871 40
Fax: +46-8-33 07 44

SE (STOCKHOLM) coordinator 0.00
2    CENTRE HOSPITALIER ET UNIVERSITAIREDE RABAT

 Organization address address: HAY RIAD
city: RABAT
postcode: 10100

contact info
Titolo: Mr.
Nome: Mohamed
Cognome: El Gueouatri
Email: send email
Telefono: 21237714386
Fax: 21237710721

MA (RABAT) participant 0.00
3    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Ms.
Nome: Annick
Cognome: Bertault
Email: send email
Telefono: 33 1 40 78 49 01
Fax: 33 1 40 78 49 98

FR (PARIS) participant 0.00
4    INSTITUT PASTEUR DE LILLE FONDATION

 Organization address address: 1 Rue du professeur Calmette
city: LILLE
postcode: 59019

contact info
Titolo: Ms.
Nome: Fabienne
Cognome: Jean
Email: send email
Telefono: +33 3 20 87 72 27
Fax: +33 3 20 87 78 73

FR (LILLE) participant 0.00
5    ISTITUTO SUPERIORE DI SANITA

 Organization address address: Viale Regina Elena 299
city: ROMA
postcode: 161

contact info
Titolo: Dr.
Nome: Rosa Maria
Cognome: Martoccia
Email: send email
Telefono: +39-06-4990 2688
Fax: +39-06-4990 3007

IT (ROMA) participant 0.00
6    LIONEX GMBH

 Organization address address: Salzdahlumer Strasse 196
city: BRAUNSCHWEIG
postcode: 38126

contact info
Titolo: Dr.
Nome: Mahavir
Cognome: Singh
Email: send email
Telefono: +49 5312601266
Fax: +49 5312601159

DE (BRAUNSCHWEIG) participant 0.00
7    STOCKHOLMS UNIVERSITET

 Organization address address: Universitetsvaegen 10
city: STOCKHOLM
postcode: 10691

contact info
Titolo: Mr.
Nome: Gelana
Cognome: Yadeta
Email: send email
Telefono: -164142
Fax: -61257

SE (STOCKHOLM) participant 0.00
8    UNIVERSITE LIBRE DE BRUXELLES

 Organization address address: Avenue Franklin Roosevelt 50
city: BRUXELLES
postcode: 1050

contact info
Titolo: Prof.
Nome: Françoise
Cognome: Mascart
Email: send email
Telefono: 32 2 5553467
Fax: 32 2 5554499

BE (BRUXELLES) participant 0.00
9    UNIVERSITY OF GLASGOW

 Organization address address: University Avenue
city: GLASGOW
postcode: G12 8QQ

contact info
Titolo: Mr.
Nome: Joe
Cognome: Galloway
Email: send email
Telefono: +44 (0)141 330 3884
Fax: +44 (0)141 330 5611

UK (GLASGOW) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

tuberculosis    mice    vaccination    individuals    pulmonary    half    responses    tb    million    infection    mycobacterial    mycobacteria    host    cell    cells    human    infected    disease    regulation    cellular    clinical    primary    immune    molecular    outcome    studied    interactions    patients   

 Obiettivo del progetto (Objective)

'Tuberculosis (TB) is a leading public health problem. About half of the 10% of Mycobacterium tuberculosis-infected individuals develop overt clinical disease, do so within two years of primary infection. The remaining half of the TB patients, develop clinical disease later, owing to “reactivation” of pulmonary TB. Of importance, it is not understood why only 10% infected individuals develop active disease. In this project, we will investigate the molecular and cellular interactions between mycobacteria and host cells, and the regulation of such interactions by cellular immune responses. Such interactions dictate the outcome of infection, ranging from asymptomatic infection to life-threatening disease. For this purpose, we have established a consortium of experts in Genetics, Immunology, Microbiology and Paediatrics and a biotechnology company. We will dissect the molecular and cellular immune responses, combining mice models, and human patients. In both approaches, the responses of various host target cells regulating mycobacterial growth and the mycobacterial adaptation to different host cell responses to infection will be studied. The role of innate and adaptive immune responses in the control of mycobacterial growth and the regulation of inflammation will be studied as well. In addition, we will investigate such responses using a third model based on mice reconstituted de novo with human hematopoietic-derived cell lineages. Finally, targeted and genome-wide explorations will be employed in large familial samples to identify novel susceptibility genes involved in the immune control of primary M. tuberculosis infection and secondary pulmonary TB. The outcome of HOMITB will be an assessment of molecular and cellular interactions crucial for the design of novel vaccination, immunotherapeutic strategies and better diagnostic biomarkers. The feasibility of this programme is attested by the high scientific quality and remarkable complementarities of the participants.'

Introduzione (Teaser)

Tuberculosis rates are on the rise worldwide, with 8.8 million new cases and 2 million deaths being recorded each year. Better understanding the interactions between host and mycobacteria is vital for designing vaccination or immunotherapies.

Altri progetti dello stesso programma (FP7-HEALTH)

WINTHER (2013)

WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients

Read More  

COMPLEXINC (2011)

New Technologies and Production Tools for Complex Protein Biologics

Read More  

INYVAX (2009)

"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges."

Read More